MA30153B1 - Anticorps anti-ox40l et methodes correspondantes - Google Patents
Anticorps anti-ox40l et methodes correspondantesInfo
- Publication number
- MA30153B1 MA30153B1 MA31104A MA31104A MA30153B1 MA 30153 B1 MA30153 B1 MA 30153B1 MA 31104 A MA31104 A MA 31104A MA 31104 A MA31104 A MA 31104A MA 30153 B1 MA30153 B1 MA 30153B1
- Authority
- MA
- Morocco
- Prior art keywords
- corresponding methods
- ox40l antibodies
- ox40l
- antibodies
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Abstract
L'invention fournit des anticorps anti-OX40L, des compositions les comportant et méthodes correspondantes.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75137705P | 2005-12-16 | 2005-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30153B1 true MA30153B1 (fr) | 2009-01-02 |
Family
ID=38616368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31104A MA30153B1 (fr) | 2005-12-16 | 2008-07-11 | Anticorps anti-ox40l et methodes correspondantes |
Country Status (18)
Country | Link |
---|---|
US (2) | US7812133B2 (fr) |
EP (1) | EP1973949A2 (fr) |
JP (1) | JP2009519718A (fr) |
KR (1) | KR20080080639A (fr) |
CN (1) | CN101374865A (fr) |
AR (1) | AR057253A1 (fr) |
AU (1) | AU2006343459A1 (fr) |
BR (1) | BRPI0621065A2 (fr) |
CA (1) | CA2633602A1 (fr) |
CR (1) | CR10069A (fr) |
EC (1) | ECSP088543A (fr) |
IL (1) | IL191820A0 (fr) |
MA (1) | MA30153B1 (fr) |
NO (1) | NO20083147L (fr) |
RU (1) | RU2426744C2 (fr) |
TW (1) | TW200732349A (fr) |
WO (1) | WO2007133290A2 (fr) |
ZA (1) | ZA200804868B (fr) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7291331B1 (en) | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
US8076650B2 (en) | 2006-07-14 | 2011-12-13 | Fei Company | Multi-source plasma focused ion beam system |
KR20100014588A (ko) * | 2007-02-27 | 2010-02-10 | 제넨테크, 인크. | 길항제 ox40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도 |
US20090309617A1 (en) * | 2007-08-24 | 2009-12-17 | Ye Fang | Biosensor antibody functional mapping |
WO2009141239A1 (fr) * | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | Formulation pharmaceutique comprenant un anticorps contre ox40l, utilisations de celle-ci |
US8518405B2 (en) * | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
EP2513145B1 (fr) * | 2009-12-14 | 2018-01-24 | Ablynx N.V. | Domaines variables uniques de liaison anti-ox40l, construits et application therapeutique |
US20120020960A1 (en) * | 2010-07-26 | 2012-01-26 | Baylor Research Institute | Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer |
MY171312A (en) | 2010-08-23 | 2019-10-08 | Univ Texas | Anti-ox40 antibodies and methods of using the same |
US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
CN106977604A (zh) | 2011-04-21 | 2017-07-25 | 百时美施贵宝公司 | 拮抗cd40之抗体多肽 |
AU2012299421B2 (en) * | 2011-08-23 | 2016-02-04 | Board Of Regents, The University Of Texas System | Anti-OX40 antibodies and methods of using the same |
AU2014317884B2 (en) | 2013-09-09 | 2017-09-07 | Canimguide Therapeutics Ab | Immune system modulators |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
JP2017165652A (ja) * | 2014-06-30 | 2017-09-21 | 国立大学法人東北大学 | 新規抗ヒトox40リガンド抗体、及びこれを含む抗インフルエンザ薬 |
CN107074951B (zh) * | 2014-08-04 | 2021-08-03 | 贝勒研究院 | 拮抗性抗-ox40l抗体及其使用方法 |
US11554181B2 (en) | 2014-09-05 | 2023-01-17 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
US9512229B2 (en) | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
CN114504652A (zh) * | 2015-03-03 | 2022-05-17 | 科马布有限公司 | 抗体、用途和方法 |
US9434785B1 (en) | 2015-04-30 | 2016-09-06 | Kymab Limited | Anti-human OX40L antibodies and methods of treating graft versus host disease with the same |
US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
ES2853582T3 (es) | 2015-03-06 | 2021-09-16 | Canimguide Therapeutics Ab | Moduladores del sistema inmune y composiciones |
KR20180015650A (ko) | 2015-05-07 | 2018-02-13 | 아게누스 인코포레이티드 | 항-ox40 항체 및 이의 사용 방법 |
CA3007233A1 (fr) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Anticorps et leurs methodes d'utilisation |
DE102016105069A1 (de) | 2016-03-18 | 2017-09-21 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Antivirale Immuntherapie durch Membranrezeptorligation |
US11065301B2 (en) | 2016-04-15 | 2021-07-20 | Pontificia Universidad Catolica De Chile | Pharmaceutical composition for ameliorating the symptoms and disease of the respiratory infection caused by human metapneumovirus (HMPV), which comprises at least one agent that neutralizes the function of TSLP and/or TSLPR and/or OX40L and/or CD177 molecules, and a pharmaceutically acceptable excipient, and use thereof |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
CN109689688B (zh) | 2016-08-09 | 2023-06-13 | 科马布有限公司 | 抗icos抗体 |
WO2018083248A1 (fr) | 2016-11-03 | 2018-05-11 | Kymab Limited | Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés |
MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
WO2019122882A1 (fr) | 2017-12-19 | 2019-06-27 | Kymab Limited | Anticorps bispécifique pour icos et pd-l1 |
GB202012331D0 (en) * | 2020-08-07 | 2020-09-23 | Petmedix Ltd | Therapeutic antibodies |
CN114437228B (zh) * | 2020-10-30 | 2024-02-06 | 中国科学院生物物理研究所 | 一种il-2与抗体亚单位构成的双功能融合蛋白 |
IL310701A (en) * | 2021-08-10 | 2024-04-01 | Kymab Ltd | Treatment of atopic dermatitis |
WO2023152486A1 (fr) * | 2022-02-09 | 2023-08-17 | Petmedix Ltd | Anticorps thérapeutiques |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
US5821332A (en) | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
US6242566B1 (en) | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
JP3914342B2 (ja) | 1997-09-25 | 2007-05-16 | 武田薬品工業株式会社 | gp34結合阻害物を有効成分として含有する医薬組成物 |
CA2410188A1 (fr) * | 2000-06-06 | 2001-12-13 | Idec Pharmaceutical Corporation | Anticorps non agonistiques diriges contre gp 39 humaine, compositions les contenant et leur utilisation therapeutique |
FR2822846B1 (fr) | 2001-04-03 | 2004-01-23 | Technopharm | Procede de preparation et de selection d'anticorps |
GB0123276D0 (en) | 2001-09-27 | 2001-11-21 | Imp College Innovations Ltd | Uses of agents that bind immune-system components |
JP3926596B2 (ja) | 2001-09-28 | 2007-06-06 | 独立行政法人科学技術振興機構 | Ox40l遺伝子を導入した自己免疫疾患モデル非ヒト哺乳動物 |
AU2002365814A1 (en) | 2001-12-18 | 2003-07-30 | J And J Research Pty Ltd | Method of treating asthma |
IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
US20040136992A1 (en) | 2002-08-28 | 2004-07-15 | Burton Paul B. J. | Compositions and method for treating cardiovascular disease |
US7291331B1 (en) | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
JP2007530045A (ja) | 2004-03-23 | 2007-11-01 | アムジエン・インコーポレーテツド | ヒトox40l(cd134l)特異性モノクローナル抗体 |
JP2006081061A (ja) | 2004-09-13 | 2006-03-23 | Alpine Electronics Inc | 音声出力装置及び音声/映像出力装置 |
TWI380996B (zh) * | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
KR20100014588A (ko) | 2007-02-27 | 2010-02-10 | 제넨테크, 인크. | 길항제 ox40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도 |
-
2006
- 2006-12-15 BR BRPI0621065-1A patent/BRPI0621065A2/pt not_active IP Right Cessation
- 2006-12-15 CA CA002633602A patent/CA2633602A1/fr not_active Abandoned
- 2006-12-15 EP EP06851330A patent/EP1973949A2/fr not_active Withdrawn
- 2006-12-15 ZA ZA200804868A patent/ZA200804868B/xx unknown
- 2006-12-15 WO PCT/US2006/062173 patent/WO2007133290A2/fr active Application Filing
- 2006-12-15 KR KR1020087017186A patent/KR20080080639A/ko not_active Application Discontinuation
- 2006-12-15 US US12/097,733 patent/US7812133B2/en active Active
- 2006-12-15 CN CNA2006800529729A patent/CN101374865A/zh active Pending
- 2006-12-15 AR ARP060105564A patent/AR057253A1/es not_active Application Discontinuation
- 2006-12-15 TW TW095147231A patent/TW200732349A/zh unknown
- 2006-12-15 RU RU2008129111/10A patent/RU2426744C2/ru not_active IP Right Cessation
- 2006-12-15 JP JP2008545995A patent/JP2009519718A/ja not_active Withdrawn
- 2006-12-15 AU AU2006343459A patent/AU2006343459A1/en not_active Abandoned
-
2008
- 2008-05-29 IL IL191820A patent/IL191820A0/en unknown
- 2008-06-12 CR CR10069A patent/CR10069A/es not_active Application Discontinuation
- 2008-06-13 EC EC2008008543A patent/ECSP088543A/es unknown
- 2008-07-11 MA MA31104A patent/MA30153B1/fr unknown
- 2008-07-15 NO NO20083147A patent/NO20083147L/no not_active Application Discontinuation
-
2010
- 2010-07-12 US US12/834,748 patent/US20100272738A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NO20083147L (no) | 2008-09-16 |
US20090053230A1 (en) | 2009-02-26 |
RU2008129111A (ru) | 2010-01-27 |
CR10069A (es) | 2008-10-10 |
BRPI0621065A2 (pt) | 2011-11-29 |
RU2426744C2 (ru) | 2011-08-20 |
EP1973949A2 (fr) | 2008-10-01 |
ECSP088543A (es) | 2008-07-30 |
KR20080080639A (ko) | 2008-09-04 |
US20100272738A1 (en) | 2010-10-28 |
JP2009519718A (ja) | 2009-05-21 |
WO2007133290A8 (fr) | 2008-03-27 |
CN101374865A (zh) | 2009-02-25 |
IL191820A0 (en) | 2008-12-29 |
US7812133B2 (en) | 2010-10-12 |
CA2633602A1 (fr) | 2007-11-22 |
ZA200804868B (en) | 2009-10-28 |
AU2006343459A1 (en) | 2007-11-22 |
AR057253A1 (es) | 2007-11-21 |
WO2007133290A3 (fr) | 2008-01-10 |
TW200732349A (en) | 2007-09-01 |
WO2007133290A2 (fr) | 2007-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30153B1 (fr) | Anticorps anti-ox40l et methodes correspondantes | |
CY2018013I1 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
RS50660B (sr) | Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže | |
PH12015500550A1 (en) | Anti-notch1 nrr antibodies and methods using same | |
MA31231B1 (fr) | Anticorps anti-robo4 et utilisations de ceux-ci | |
CY1118343T1 (el) | Αντισωματα συνδεσης twεακ | |
NO20083397L (no) | Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse | |
MA30910B1 (fr) | Anticorps et immunoconjugues, et leurs utilisations | |
WO2007136893A3 (fr) | Anticorps anti fgf19 et leurs méthodes d'utilisation | |
MA33208B1 (fr) | Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci | |
TW200626171A (en) | Fixed dosing of HER antibodies | |
ATE525913T2 (de) | Fettzusammensetzungen | |
EA200701918A1 (ru) | Белок липокалин | |
WO2006083936A3 (fr) | Anticorps anti-ephb2 et methodes d'utilisation associees | |
TW200709817A (en) | Platform antibody compositions | |
NO20090047L (no) | Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse | |
MX341370B (es) | Antagonistas anti - beta7 humanizados y usos para los mismos. | |
CY1109916T1 (el) | Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις | |
TW200738751A (en) | Anti-EphrinB2 antibodies and methods using same | |
EA200702193A1 (ru) | Гликозилирование белков | |
EA200600404A1 (ru) | Пероральные препаративные формы кладрибина | |
ATE499341T1 (de) | 5-(2,2-dimethyl-cyclopropyl)-3-methylpent-2- ennitril als geruchs- und geschmacksstoff | |
FR2894983B1 (fr) | Test de caracterisation des anticorps. | |
WO2007073567A3 (fr) | Compositions et procedes pour la modulation de la reponse immunitaire | |
WO2007002096A3 (fr) | Methodes et compositions permettant de cibler ifnar2 |